UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A pregnancy physiologically based pharmacokinetic (p‐PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4

British journal of clinical pharmacology, 2012-11, Vol.74 (5), p.873-885

2012

Volltextzugriff (PDF)

Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

Pharmaceutical research, 2012-10, Vol.29 (10), p.2860-2873

2012

Volltextzugriff (PDF)

Effects of Pregnancy on CYP3A and P-glycoprotein Activities as Measured by Disposition of Midazolam and Digoxin: A University of Washington Specialized Center of Research Study

Clinical pharmacology and therapeutics, 2008-08, Vol.84 (2), p.248-253

2008

Volltextzugriff (PDF)

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

Drug metabolism and disposition, 2008-02, Vol.36 (2), p.386-399

2008

Volltextzugriff (PDF)

Imatinib Disposition and ABCB1 (MDR1, P‐Glycoprotein) Genotype

Clinical pharmacology and therapeutics, 2007-07, Vol.82 (1), p.33-40

2007

Volltextzugriff (PDF)

Intratumoral Estrogen Disposition in Breast Cancer

Clinical cancer research, 2010-03, Vol.16 (6), p.1790-1801

2010

Volltextzugriff (PDF)

Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV

Drug metabolism and disposition, 2005-04, Vol.33 (4), p.587-595

2005

Volltextzugriff (PDF)

Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants

Pharmacogenetics and genomics, 2007-08, Vol.17 (8), p.647-656

2007

Volltextzugriff (PDF)

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

Drug metabolism and disposition, 2010-04, Vol.38 (4), p.667-678

2010

Volltextzugriff (PDF)

Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans

Drug metabolism and disposition, 2011-02, Vol.39 (2), p.215-227

2011

Volltextzugriff (PDF)

CYP2A6 genotype and the metabolism and disposition kinetics of nicotine

Clinical pharmacology and therapeutics, 2006-11, Vol.80 (5), p.457-467

2006

Volltextzugriff (PDF)

Phase I, Open-Label, Safety and Pharmacokinetic Study To Assess Bronchopulmonary Disposition of Intravenous Eravacycline in Healthy Men and Women

Antimicrobial agents and chemotherapy, 2014-04, Vol.58 (4), p.2113-2118

2014

Volltextzugriff (PDF)

A Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts Intestinal First-pass Metabolism in Children

Clinical pharmacokinetics, 2014-12, Vol.53 (12), p.1171-1182

2014

Volltextzugriff (PDF)

Metabolism and disposition of imatinib mesylate in healthy volunteers

Drug metabolism and disposition, 2005-10, Vol.33 (10), p.1503-1512

2005

Volltextzugriff (PDF)

CYP3A5 and CYP3A4 but not MDR1 Single‐nucleotide Polymorphisms Determine Long‐term Tacrolimus Disposition and Drug‐related Nephrotoxicity in Renal Recipients

Clinical pharmacology and therapeutics, 2007-12, Vol.82 (6), p.711-725

2007

Volltextzugriff (PDF)

Pulmonary Disposition of Tedizolid following Administration of Once-Daily Oral 200-Milligram Tedizolid Phosphate in Healthy Adult Volunteers

Antimicrobial Agents and Chemotherapy, 2012-05, Vol.56 (5), p.2627-2634

2012

Volltextzugriff (PDF)

Disposition, Metabolism, and Excretion of [14C]Doripenem after a Single 500-Milligram Intravenous Infusion in Healthy Men

Antimicrobial Agents and Chemotherapy, 2008-10, Vol.52 (10), p.3478-3483

2008

Volltextzugriff (PDF)

Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe

Pharmacogenetics and genomics, 2008-05, Vol.18 (5), p.439-448

2008

Volltextzugriff (PDF)

Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme

Drug metabolism and disposition, 2007-09, Vol.35 (9), p.1657-1663

2007

Volltextzugriff (PDF)

Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients

European journal of clinical pharmacology, 2014-02, Vol.70 (2), p.155-166

2014

Volltextzugriff (PDF)

UGT1A128 polymorphism as a determinant of irinotecan disposition and toxicity

The pharmacogenomics journal, 2002, Vol.2 (1), p.43-47

2002

Volltextzugriff (PDF)

Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans

Drug metabolism and disposition, 2010-11, Vol.38 (11), p.2049-2059

2010

Volltextzugriff (PDF)

Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans

Clinical pharmacology and therapeutics, 2008-07, Vol.84 (1), p.95-103

2008

Volltextzugriff (PDF)

Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast‐feeding

British journal of clinical pharmacology, 2006-02, Vol.61 (2), p.155-163

2006

Volltextzugriff (PDF)

Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism

Drug metabolism and disposition, 2003-01, Vol.31 (1), p.98-107

2003

Volltextzugriff (PDF)

1 – 25 von 8.037

Suche als RSS-Feed

Aktive Filter

SpracheKoreanisch

SpracheEnglisch

ThemaAdult

ThemaPharmacology. Drug Treatments

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(7.831)
Mit Volltextzugriff
(5.753)

Publikationsform

Artikel
(8.037)

Erscheinungsjahr

n.n

Thema

Biological And Medical Sciences
(8.037)
Medical Sciences
(8.037)
Humans
(8.036)
Science & Technology
(7.452)
Life Sciences & Biomedicine
(7.442)
Male
(6.989)
Pharmacology & Pharmacy
(5.581)
Female
(5.548)
Middle Aged
(4.522)
Aged
(2.579)
Adolescent
(1.710)
Neuropharmacology
(1.631)
Administration, Oral
(1.497)
Pharmacokinetics
(1.381)
Half-Life
(1.234)
Area Under Curve
(1.184)
Double-Blind Method
(1.146)
Dose-Response Relationship, Drug
(1.051)

13 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(8.037)
WK Lippincott Williams & Wilkins–Connect here FIRST to enable access
(5.478)
Wiley Online Library Journals
(4.142)
Ingenta
(3.124)
Wiley Online Library Full Collection 2018
(2.991)
EZB Electronic Journals Library
(2.887)
NUS Single-Journal Subscriptions
(2.250)
IngentaConnect Journals
(1.985)
SpringerLink_现刊
(1.180)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(867)
Elsevier ScienceDirect Journals Complete
(576)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(416)
Nexis Uni
(257)
Oxford journals
(184)
SAGE Publications
(162)
Oxford Journals 2020 Medicine
(155)
Taylor & Francis Online
(122)
Taylor & Francis
(115)
Nature Journals
(106)
Taylor & Francis Journals
(90)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A pregnancy physiologically based pharmacokinetic (p‐PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4

Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

Effects of Pregnancy on CYP3A and P-glycoprotein Activities as Measured by Disposition of Midazolam and Digoxin: A University of Washington Specialized Center of Research Study

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

Imatinib Disposition and ABCB1 (MDR1, P‐Glycoprotein) Genotype

Intratumoral Estrogen Disposition in Breast Cancer

Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV

Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans

CYP2A6 genotype and the metabolism and disposition kinetics of nicotine

Phase I, Open-Label, Safety and Pharmacokinetic Study To Assess Bronchopulmonary Disposition of Intravenous Eravacycline in Healthy Men and Women

A Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts Intestinal First-pass Metabolism in Children

Metabolism and disposition of imatinib mesylate in healthy volunteers

CYP3A5 and CYP3A4 but not MDR1 Single‐nucleotide Polymorphisms Determine Long‐term Tacrolimus Disposition and Drug‐related Nephrotoxicity in Renal Recipients

Pulmonary Disposition of Tedizolid following Administration of Once-Daily Oral 200-Milligram Tedizolid Phosphate in Healthy Adult Volunteers

Disposition, Metabolism, and Excretion of [14C]Doripenem after a Single 500-Milligram Intravenous Infusion in Healthy Men

Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe

Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme

Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients

UGT1A128 polymorphism as a determinant of irinotecan disposition and toxicity

Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans

Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans

Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast‐feeding

Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism

Aktive Filter

Suchergebnisse filtern